Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Cellectis S.A. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 31 | 1 | 27 | −3 |
| Shares | 9.85M | 1.44M | 9.77M | +1.36M (+16.1%) |
| Value | $26.1M | $3.81M | $18.3M | −$4.03M (−18.1%) |
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Cellectis S.A. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Asset Management Americas Inc | 1,438,255 | $2.69M | 0.00% |
| Citadel Advisors LLC | 26,699 | $49.9K | 0.00% |
| XTX Topco Ltd | 15,320 | $28.6K | 0.00% |
| Baird Financial Group, Inc. | 15,090 | $28.2K | 0.00% |
Sold out (7)
Institutions that held Cellectis S.A. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Oppenheimer & Co Inc | 133,890 | $354.8K |
| Susquehanna International Group, LLP | 27,655 | $73.3K |
| Group One Trading, L.P. | 1,523 | $4.04K |
| Advisor Group Holdings, Inc. | 1,080 | $2.86K |
| Old Point Trust & Financial Services N A | 250 | $663 |
| FRG Family Wealth Advisors LLC | 80 | $205 |
| Sofos Investments, Inc. | 1 | $3 |
Not filed for Q2 2024 yet (1)
Institutions that held Cellectis S.A. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 1,438,255 | $3.81M |